These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35303463)

  • 1. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.
    Koroma JA; Elduma AH; Sesay U; Gebru GN
    BMC Infect Dis; 2024 Jun; 24(1):579. PubMed ID: 38862873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T; Ncayiyana J; Padanilam X; Nyasulu PS
    BMC Infect Dis; 2015 Oct; 15():478. PubMed ID: 26511616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa.
    Lotz JK; Porter J; Conradie H; Boyles T; Gaunt B; Dimanda S; Cort D
    S Afr Med J; 2023 Nov; 113(11):47-56. PubMed ID: 38525642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone.
    Blankson HNA; Kamara RF; Barilar I; Andres S; Conteh OS; Dallenga T; Foray L; Maurer F; Kranzer K; Utpatel C; Niemann S
    Microbiol Spectr; 2024 Mar; 12(3):e0240523. PubMed ID: 38289066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.
    Panford V; Kumah E; Kokuro C; Adoma PO; Baidoo MA; Fusheini A; Ankomah SE; Agyei SK; Agyei-Baffour P
    BMJ Open; 2022 Jul; 12(7):e062857. PubMed ID: 35790328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.
    Jones-López EC; Ayakaka I; Levin J; Reilly N; Mumbowa F; Dryden-Peterson S; Nyakoojo G; Fennelly K; Temple B; Nakubulwa S; Joloba ML; Okwera A; Eisenach KD; McNerney R; Elliott AM; Ellner JJ; Smith PG; Mugerwa RD
    PLoS Med; 2011 Mar; 8(3):e1000427. PubMed ID: 21423586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
    BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: A thirteen-year analysis.
    Matulyte E; Davidaviciene E; Kancauskiene Z; Diktanas S; Kausas A; Velyvyte D; Urboniene J; Lipnickiene V; Laurencikaite M; Danila E; Costagliola D; Matulionyte R
    PLoS One; 2023; 18(3):e0282046. PubMed ID: 36952578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study.
    Van LH; Phu PT; Vinh DN; Son VT; Hanh NT; Nhat LTH; Lan NH; Vinh TV; Trang NTM; Ha DTM; Thwaites GE; Thuong NTT
    BMC Infect Dis; 2020 Feb; 20(1):164. PubMed ID: 32087682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.
    Mpagama SG; Heysell SK; Ndusilo ND; Kumburu HH; Lekule IA; Kisonga RM; Gratz J; Boeree MJ; Houpt ER; Kibiki GS
    PLoS One; 2013; 8(5):e62034. PubMed ID: 23675411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment outcomes of adult tuberculosis in an urban setting with high HIV prevalence in Sierra Leone: A retrospective study.
    Lakoh S; Jiba DF; Adekanmbi O; Poveda E; Sahr F; Deen GF; Foray LM; Gashau W; Hoffmann CJ; Salata RA; Yendewa GA
    Int J Infect Dis; 2020 Jul; 96():112-118. PubMed ID: 32339724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
    Jaber AAS; Ibrahim B
    BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.